Nivolumab Plus Ibrutinib in Patients With DLBCL Richter Transformation of CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL
Blood Adv 2022 Oct 26;[EPub Ahead of Print], N Jain, J Senapati, B Thakral, A Ferrajoli, PA Thompson, JA Burger, S Basu, TM Kadia, NG Daver, G Borthakur, M Konopleva, N Pemmaraju, EM Parry, CJ Wu, JD Khoury, CE Bueso-Ramos, N Garg, X Wang, W Lopez, A Ayala, SM O'Brien, HM Kantarjian, MJ Keating, JP Allison, P Sharma, WG WierdaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.